Rose F. Kennedy Intellectual and Developmental Disabilities Research Center

Overview (old)

Founded more than 40 years ago, the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (RFK IDDRC) has long been at the forefront of research on brain development and function, while simultaneously providing clinical care for children with intellectual and developmental disabilities (IDDs). It is also one of the oldest designated University Centers for Excellence in Developmental Disabilities Research, Education and Service (UCEDD) and, as such, has intimate links to Einstein’s UCEDD clinical arm - the Children’s Evaluation and Rehabilitation Center (CERC).

CERC provides clinicians and investigators with the challenge and opportunity of working with large numbers of IDD-related conditions in the genetically diverse and socioeconomically compromised population of the Bronx.

Demonstrating further integration within Einstein’s RFK IDDRC, the UCEDD is also home to the Leadership Education in Neurodevelopmental Disabilities (LEND) Program, one of only 38 in the United States, which supports interdisciplinary clinical training for medical and allied health professionals who care for individuals with special healthcare needs.




Steven Walkley, DVM, PhD 
Albert Einstein College of Medicine 


Lysosomal Disease at Half Century: A New Era Emerges
January 23, 2015  
John D. Wiley Conference Center

Dr. Steven Walkley, Einstein Professor of Neuroscience, Pathology and Neurology and Director of the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, was chosen as the University of Wisconsin’s 2015 Harry Waisman Memorial Lecturer. Dr. Walkley’s talk, at the John D. Wiley Conference Center on January 23, 2015, entitled “Lysosomal Disease at Half Century: A New Era Emerges,” provided a historical overview of the challenges faced by researchers in the early years after discovery, of this group of devastating diseases. He then went on to highlight how recent discoveries and advances in medical research have led to an expanded understanding of the importance of the lysosomal system as well as to multiple therapeutic approaches, ranging from gene therapy, enzyme replacement, substrate reduction, the use of proteostasis regulators, etc.


3rd Annual Isabelle Rapin Conference on Communication Disorders: Rett Syndrome  (Wednesday, December 10, 2014) 

On a rainy Wednesday in early December, over 100 doctors and scientists crowded into the Price Center’s LeFrak Auditorium to hear keynote speakers Dr. Huda Zoghbi of the Baylor College of Medicine, Dr. Michael Green of the University of Massachusetts Medical School, and Monica Coenraads, executive director of the Rett Syndrome Research Trust (RSRT), along with faculty from the Albert Einstein College of Medicine/Montefiore Medical Center, present on many topics ranging from advances in translational research to novel therapeutic approaches related to some of the most common comorbidities specific to Rett Syndrome patients.



Related News & Features

read more

A Message From the Director

Dr Steven Walkley

Steven U. Walkley, D.V.M., Ph.D.

Most intellectual and developmental disabilities, particularly those with genetic causes, not only predominantly affect children but are also rare—as defined by the Rare Disease Act of 2002, they affect about 1 in 1,500 people. There are estimated to be almost 7,000 rare diseases, most of which are in fact ultra-rare, read more... 


Watch video on Dr. Walkley's rare disease research.

legacy series
featured investigator

In the Media

Wall Street Journal interviews Drs. Kartik Chandran and Steven Walkley about the connection between the rare genetic disease Niemann-Pick Type C and Ebola. (subscription) (Monday, Nov 03, 2014)

Time features research led by Dr. Sophie Molholm suggesting that brain scans measuring how quickly children process sensory information could be used to diagnose autism. (Monday, Sep 22, 2014)

media coverage on other stories

Click here to log in

Research Round-Up

Elective ServiceDr. Susan Band Horwitz was elected to serve as one of the members of the AACR Nominating Committee for the 2012 to 2014 term. Founded in 1907, the AACR (American Association for Cancer Research), is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. Its membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. Dr. Horwitz is distinguished university professor and co-chair of molecular pharmacology at Einstein, as well as associate director for therapeutics for the Albert Einstein Cancer Center and the Rose C. Falkenstein Professor of Cancer Research. She also is an AACR past president and currently serves as a member on the Council of Scientific Advisors.

Good Reading Dr. U. Thomas Meier was awarded a $1.2 million grant over four years by the National Institute of General Medical Sciences to study how cells assemble small nucleolar RNA-protein complexes that function in the modification of ribosomal and other RNAs, thereby fine-tuning protein synthesis and pre-messenger RNA processing.  Dr. Meier’s laboratory will use novel approaches to shed light on these basic cellular processes, thus providing the foundation for understanding what goes wrong in certain genetic diseases and cancers.  Dr. Meier is professor of anatomy and structural biology.

read more